Naturally occurring immunopeptide may tackle the ‘root cause’ of obesity-related conditions: Research shows that an immunopeptide called PEPITEM could provide a revolutionary approach to reducing the risk of obesity-related diseases such as type 2 diabetes and hepatic steatosis (fatty liver). PEPITEM was first identified in 2015 by University of Birmingham researchers who described its role in the immunomodulatory adiponectin-PEPITEM pathway that is dysregulated in immune-mediated inflammatory diseases, including rheumatoid arthritis and type-1-diabetes. The latest research, published in Clinical & Experimental Immunology, highlights the potential for PEPITEM as a novel therapy to reduce systemic inflammation and tissue damage that underpins the
Reducing the risk of obesity-related diseases as seen on The Hippocratic Post.